1. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Issue 12 (December 2022) Authors: Zhao, Fang-Hui; Wu, Ting; Hu, Yue-Mei; Wei, Li-Hui; Li, Ming-Qiang; Huang, Wei-Jin; Chen, Wen; Huang, Shou-Jie; Pan, Qin-Jing; Zhang, Xun; Hong, Ying; Zhao, Chao; Li, Qing; Chu, Kai; Jiang, Yun-Fei; Li, Ming-Zhu; Tang, Jie; Li, Cai-Hong; Guo, Dong-Ping; Ke, Li-Dong Journal: Lancet infectious diseases Issue: Volume 22:Issue 12(2022) Page Start: 1756 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗